David A. Siegel Tyra Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 12,300 shares of TYRA stock, worth $154,857. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,300Holding current value
$154,857% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TYRA
# of Institutions
111Shares Held
43.1MCall Options Held
3.8KPut Options Held
6K-
Ra Capital Management, L.P. Boston, MA10.6MShares$134 Million2.39% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.18MShares$52.6 Million97.27% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$51.4 Million89.47% of portfolio
-
Nextech Invest Ag4.06MShares$51.1 Million10.51% of portfolio
-
Bvf Inc San Francisco, CA3.94MShares$49.7 Million2.05% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $528M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...